Overview of the role of nanotechnological innovations in the detection and treatment of solid tumors

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 589-613

  Frank, Derusha ^a   Tyagi, Charu ^a   Tomar, Lomas ^a   Choonara, Yahya E ^a   du Toit, Lisa C ^a   Kumar, Pradeep ^a   Penny, Clement ^a   Pillay, Viness ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Antineoplastic drugs; Nanosystems; Nanotheranostics; Poor aqueous solubility; Solid tumors; Targeted drug delivery

Indexed keywords

ANTINEOPLASTIC AGENT; APTAMER; BENZO[A]PYRENE; CAMPTOTHECIN; CARBON NANOTUBE; CYANOACRYLATE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FOLATE RECEPTOR 1; GOLD NANOPARTICLE; HEAT SHOCK PROTEIN 90; HERMES ANTIGEN; HYALURONIC ACID; LIPOSOME; MAGNETIC NANOPARTICLE; NANOCRYSTAL; NANOFIBER; NANOMATERIAL; NANOTUBE; POLY(ISOBUTYL 2 CYANOACRYLATE); POLYGLACTIN; POLYLACTIC ACID; QUANTUM DOT; TANESPIMYCIN; TELOMERASE; TRASTUZUMAB; TUMOR MARKER; UNINDEXED DRUG; VASCULOTROPIN;

AQUEOUS SOLUTION; BIOSENSOR; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER THERAPY; COLORECTAL CANCER; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; EARLY DIAGNOSIS; HUMAN; IMAGING SYSTEM; MEDICAL RESEARCH; MICELLE; MINIMALLY INVASIVE PROCEDURE; MOLECULARLY TARGETED THERAPY; MULTIDRUG RESISTANCE; NANOENCAPSULATION; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; OVERALL SURVIVAL; QUALITY OF LIFE; REVIEW; SOLID TUMOR; SURVIVAL RATE;

ANTINEOPLASTIC DRUGS; NANOSYSTEMS; NANOTHERANOSTICS; POOR AQUEOUS SOLUBILITY; SOLID TUMORS; TARGETED DRUG DELIVERY;

ANTINEOPLASTIC AGENTS; BIOSENSING TECHNIQUES; DIAGNOSTIC IMAGING; HUMANS; NANOMEDICINE; NANOPARTICLES; NEOPLASMS;

EID: 84892836239     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S50941     Document Type: Review

References (136)

1. World Health Organization. Cancer Fact Sheet No 297. Geneva: World Health Organization; 2013. Available from: http://www.who.int/media-centre/factsheets/fs297/en/index.html. Accessed January 31, 2013.
2. McCormack VA, Schüz J. Africa's growing cancer burden: environmental and occupational contributions. Cancer Epidemiol. 2012;36(1):1-7.
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr. Accessed 30, October 2013.
4. National Cancer Institute. What Is Cancer? Defining Cancer. Bethesda, MD: National Cancer Institute. Available from: http://www.cancer.gov/cancertopics/cancerlibrary/what-is-cancer. Accessed February 28, 2013.
5. Ramasamy K, Agarwal R. Multitargeted therapy of cancer by silymarin. Cancer Lett. 2008;269(2):352-362.
6. Khosravi-Darani K, Pardakhty A, Honarpisheh H, Rao VS, Mozafari MR. The role of high-resolution imaging in the evaluation of nanosystems for bioactive encapsulation and targeted nanotherapy. Micron. 2007;38(8):804-818.
7. Rai P, Mallidi S, Zheng X, et al. Development and applications of photo-triggered theranostic agents. Adv Drug Deliv Rev. 2010;62(11): 1094-1124.
8. Bawarski WE, Chidlowsky E, Bharali DJ, Mousa SA. Emerging nanopharmaceuticals. Nanomedicine. 2008;4(4):273-282.
9. Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM, McCullough J. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine. 2013;9(1): 1-14.
10. Farokhzad OC, Langer R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv Drug Deliv Rev. 2006;58(14): 1456-1459.
11. Dominguez AL, Lustgarten J. Targeting the tumor microenvironment with anti-neu/anti-CD40 conjugated nanoparticles for the induction of antitumor immune responses. Vaccine. 2010;28(5):1383-1390.
12. Chen K-I, Li B-R, Chen Y-T. Silicon nanowire field-effect transistorbased biosensors for biomedical diagnosis and cellular recording investigation. Nano Today. 2011;6(2):131-154.
13. Vizirianakis IS. Nanomedicine and personalized medicine toward the application of pharmacotyping in clinical practice to improve drugdelivery outcomes. Nanomedicine. 2011;7(1):11-17.
14. Ji XT, Huang L, Huang HQ. Construction of nanometer cisplatin core-ferritin (NCC-F) and proteomic analysis of gastric cancer cell apoptosis induced with cisplatin released from the NCC-F. J Proteomics. 2012;75(11):3145-3157.
15. Chen H, Wang L, Yeh J, et al. Reducing non-specific binding and uptake of nanoparticles and improving cell targeting with an antifouling PEO-b-PgammaMPS copolymer coating. Biomaterials. 2010;31(20): 5397-5407.
16. Ranganathan R, Madanmohan S, Kesavan A, et al. Nanomedicine: towards development of patient-friendly drug-delivery systems for oncological applications. Int J Nanomedicine. 2017:1043-1060.
17. Jabir NR, Tabrez S, Ashraf GM, Shakil S, Damanhouri GA, Kamal MA. Nanotechnology-based approaches in anticancer research. Int J Nanomedicine. 2017:4391-4408.
18. Fishman DA, Cohen L, Blank SV, et al. The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. Am J Obstet Gynecol. 2005;192(4):1214-1221.
19. Wu X, Jiang H, Zheng J, et al. Highly sensitive recognition of cancer cells by electrochemical biosensor based on the interface of gold nanoparticles/polylactide nanocomposites. J Electroanal Chem. 2011; 656(1-2):174-178.
20. Vo-Dinh T, Cullum BM, Stokes DL. Nanosensors and biochips: frontiers in biomolecular diagnostics. Sens Actuators. 2001;74(1-3):2-11.
21. Kwon OS, Park SJ, Jang J. A high-performance VEGF aptamer functionalized polypyrrole nanotube biosensor. Biomaterials. 2010;31(17): 4740-4747.
22. National Institutes of Health. Advances in Colorectal Cancer Research: Nanotechnology to Improve Early Detection and Treatment of Colorectal Cancer. Bethesda, MD: National Institutes of Health. Available from: http://www.nih.gov/science/colorectalcancer/nanotech.htm. Accessed May 31, 2013.
23. Zheng XT, Li CM. Single living cell detection of telomerase overexpression for cancer detection by an optical fiber nanobiosensor. Biosens Bioelectron. 2010;25(6):1548-1552.
24. Geszke M, Murias M, Balan L, et al. Folic acid-conjugated core/ shell ZnS:Mn/ZnS quantum dots as targeted probes for two photon fluorescence imaging of cancer cells. Acta Biomater. 2011;7(3): 1327-1338.
25. Schroeder JE, Shweky I, Shmeeda H, Banin U, Gabizon A. Folate-mediated tumor cell uptake of quantum dots entrapped in lipid nanoparticles. J Control Release. 2007;124(1-2):28-34.
26. Pan J, Feng SS. Targeting and imaging cancer cells by folate-decorated, quantum dots (QDs)-loaded nanoparticles of biodegradable polymers. Biomaterials. 2009;30(6):1176-1183.
27. Papagiannaros A, Levchenko T, Hartner W, Mongayt D, Torchilin V. Quantum dots encapsulated in phospholipid micelles for imaging and quantification of tumors in the near-infrared region. Nanomedicine. 2009;5(2):216-224.
28. Siddiqui IA, Adhami VM, Chamcheu JC, Mukhtar H. Impact of nanotechnology in cancer: emphasis on nanochemoprevention. Int J Nanomedicine. 2012;7:591-605.
29. Setua S, Menon D, Asok A, Nair S, Koyakutty M. Folate receptor targeted, rare-earth oxide nanocrystals for bi-modal fluorescence and magnetic imaging of cancer cells. Biomaterials. 2010;31(4):714-729.
30. Chin PT, Buckle T, Aguirre de Miguel A, Meskers SC, Janssen RA, van Leeuwen FW. Dual-emissive quantum dots for multispectral intraoperative fluorescence imaging. Biomaterials. 2010;31(26):6823-6832.
31. Kim PS, Djazayeri S, Zeineldin R. Novel nanotechnology approaches to diagnosis and therapy of ovarian cancer. Gynecol Oncol. 2011;120(3): 393-403.
32. Cirstoiu-Hapca A, Buchegger F, Lange N, Bossy L, Gurny R, Delie F. Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice. J Control Release. 2010;144(3): 324-331.
33. Lei T, Srinivasan S, Tang Y, et al. Comparing cellular uptake and cytotoxicity of targeted drug carriers in cancer cell lines with different drug resistance mechanisms. Nanomedicine. 2011;7(3):324-332.
34. Guyton AC. Textbook of Medical Physiology. 8th ed. San Diego: Harcourt College Publishers; 1991:274.
35. Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci. 2003;18(2):113-120.
36. Beig A, Miller JM, Dahan A. Accounting for the solubility-permeability interplay in oral formulation development for poor water solubility drugs: the effect of PEG-400 on carbamazepine absorption. Eur J Pharm Biopharm. 2012;81(2):386-391.
37. Buckley ST, Fischer SM, Fricker G, Brandl M. In vitro models to evaluate the permeability of poorly soluble drug entities: challenges and perspectives. Eur J Pharm Sci. 2012;45(3):235-250.
38. Savic R, Luo L, Eisenberg A, Maysinger D. Micellar nanocontainers distribute to defined cytoplasmic organelles. Science. 2003;300(5619): 615-618.
39. Pathak P, Meziani MJ, Desai T, et al. Formation and stabilization of ibuprofen nanoparticles in supercritical fluid processing. J Supercrit Fluids. 2006;37(3):279-286.
40. Lu Y, Park K. Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs. Int J Pharm. 2013;453(1): 198-214.
41. Ganta S, Paxton JW, Baguley BC, Garg S. Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. Int J Pharm. 2009;367(1-2):179-186.
42. Ehrlich P. Collected Studies on Immunity. New York: John Wiley; 1906:442.
43. Rapoport N. Physical stimuli-responsive polymeric micelles for anticancer drug delivery. Prog Polym Sci. 2007;32:962-990.
44. Hernot S, Klibanov AL. Microbubbles in ultrasound-triggered drug and gene delivery. Adv Drug Deliv Rev. 2008;60(10):1153-1166.
45. Husseini GA, Pitt WG. Micelles and nanoparticles for ultrasonic drug and gene delivery. Adv Drug Deliv Rev. 2008;60(10):1137-1152.
46. Shapira A, Livney YD, Broxterman HJ, Assaraf YG. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist Updat. 2011;14(3):150-163.
47. Cho YW, Park SA, Han TH, et al. In vivo tumor targeting and radionuclide imaging with self-assembled nanoparticles: mechanisms, key factors, and their implications. Biomaterials. 2007;28(6): 1236-1247.
48. Geusens B, Lambert J, De Smedt SC, Buyens K, Sanders NN, Van Gele M. Ultradeformable cationic liposomes for delivery of small interfering RNA (siRNA) into human primary melanocytes. J Control Release. 2009;133(3):214-220.
49. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev. 2004;56(11): 1649-1659.
50. Guo M, Que C, Wang C, Liu X, Yan H, Liu K. Multifunctional superparamagnetic nanocarriers with folate-mediated and pH-responsive targeting properties for anticancer drug delivery. Biomaterials. 2011;32(1):185-194.
51. Blagosklonny MV. Matching targets for selective cancer therapy. Drug Discov Today. 2003;8(24):1104-1107.
52. Lehner R, Wang X, Wolf M, Hunziker P. Designing switchable nanosystems for medical application. J Control Release. 2012;161(2): 307-316.
53. Meng F, Cheng R, Deng C, et al. Intracellular drug release nanosystems. Materials Today. 2012;15(10):436-442.
54. Leamon CP, Low PS. Folate-mediated targeting: from diagnostics to drug and gene delivery. Drug Discov Today. 2001;6(1):44-51.
55. Vauthier C, Dubernet C, Chauvierre C, Brigger I, Couvreur P. Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles. J Control Release. 2003;93(2):151-160.
56. Rastogi R, Gulati N, Kotnala RK, Sharma U, Jayasundar R, Koul V. Evaluation of folate conjugated pegylated thermosensitive magnetic nanocomposites for tumor imaging and therapy. Colloids Surf B Biointerfaces. 2011;82(1):160-167.
57. Pradhan P, Giri J, Rieken F, et al. Targeted temperature sensitive magnetic liposomes for thermo-chemotherapy. J Control Release. 2010;142(1):108-121.
58. Paolino D, Licciardi M, Celia C, Giammona G, Fresta M, Cavallaro G. Folate-targeted supramolecular vesicular aggregates as a new frontier for effective anticancer treatment in in vivo model. Eur J Pharm Biopharm. 2012;82(1):94-102.
59. Wang X, Li J, Wang Y, et al. HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors. ACS Nano. 2009;3(10):3165-3174.
60. Wang X, Li J, Wang Y, et al. A folate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model. ACS Nano. 2011;5(8):6184-6194.
61. Onyüksel H, Mohanty PS, Rubinstein I. VIP-grafted sterically stabilized phospholipid nanomicellar 17-allylamino-17-demethoxy geldanamycin: a novel targeted nanomedicine for breast cancer. Int J Pharm. 2009;365(1-2):157-161.
62. Landriscina M, Amoroso MR, Piscazzi A, Esposito F. Heat shock proteins, cell survival and drug resistance: the mitochondrial chaperone TRAP1, a potential novel target for ovarian cancer therapy. Gynecol Oncol. 2010;117(2):177-182.
63. Mi Y, Liu X, Zhao J, Ding J, Feng SS. Multimodality treatment of cancer with herceptin conjugated, thermomagnetic iron oxides and docetaxel loaded nanoparticles of biodegradable polymers. Biomaterials. 2012;33(30):7519-7529.
64. Bazell R. HER-2: The making of Herceptin, a revolutionary treatment for breast cancer. New York: Random House; 1998.
65. Das M, Sahoo SK. Epithelial cell adhesion molecule targeted nutlin3a loaded immunonanoparticles for cancer therapy. Acta Biomater. 2011;7(1):355-369.
66. Paszko E, Ehrhardt C, Senge MO, Kelleher DP, Reynolds JV. Nanodrug applications in photodynamic therapy. Photodiagnosis Photodyn Ther. 2011;8(1):14-29.
67. Li X, Zhao Q, Qiu L. Smart ligand: Aptamer-mediated targeted delivery of chemotherapeutic drugs and siRNA for cancer therapy. J Control Release. 2013;171(2):152-162.
68. Soundararajan S, Wang L, Sridharan V, et al. Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells. Mol Pharmacol. 2009;76(5):984-991.
69. Yang X, Liu X, Liu Z, Pu F, Ren J, Qu X. Near-infrared light-triggered, targeted drug delivery to cancer cells by aptamer gated nanovehicles. Adv Mater. 2012;24(21):2890-2895.
70. Kang H, O'Donoghue MB, Liu H, Tan W. A liposome-based nanostructure for aptamer directed delivery. Chem Commun (Camb). 2010;46(2): 249-251.
71. Platt VM, Szoka FC Jr. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm. 2008;5(4):474-486.
72. Ganesh S, Iyer AK, Morrissey DV, Amiji MM. Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors. Biomaterials. 2013;34(13):3489-3502.
73. Gary-Bobo M, Brevet D, Benkirane-Jessel N, et al. Hyaluronic acid-functionalized mesoporous silica nanoparticles for efficient photodynamic therapy of cancer cells. Photodiagnosis Photodyn Ther. 2012;9(3):256-260.
74. Lo YL. Phospholipids as multidrug resistance modulators of the transport of epirubicin in human intestinal epithelial Caco-2 cell layers and everted gut sacs of rats. Biochem Pharmacol. 2000;60(9): 1381-1390.
75. Gao Z, Zhang L, Sun Y. Nanotechnology applied to overcome tumor drug resistance. J Control Release. 2012;162(1):45-55.
76. Win KY, Feng S-S. Effect of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials. 2005;26(15):2713-2722.
77. Dreis S, Rothweiler F, Michaelis M, Cinatl J Jr, Kreuter J, Langer K. Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles. Int J Pharm. 2007;341(1-2):207-214.
78. Wartlick H, Michaelis K, Balthasar S, Strebhardt K, Kreuter J, Langer K. Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells. J Drug Target. 2004;12(7):461-471.
79. Ertl B, Platzer P, Wirth M, Gabor F. Poly(D,L-lactic-co-glycolic acid) microspheres for sustained delivery and stabilization of camptothecin. J Control Release. 1999;61(3):305-317.
80. Mu L, Elbayoumi TA, Torchilin VP. Mixed micelles made of poly(ethylene glycol)-phosphatidylethanolamine conjugate and d-alpha-tocopheryl polyethylene glycol 1000 succinate as pharmaceutical nanocarriers for camptothecin. Int J Pharm. 2005;306(1-2):142-149.
81. Koo OM, Rubinstein I, Onyuksel H. Camptothecin in sterically stabilized phospholipid micelles: a novel nanomedicine. Nanomedicine. 2005;1(1):77-84.
82. Fang JY, Hung CF, Hua SC, Hwang TL. Acoustically active perfluorocarbon nanoemulsions as drug delivery carriers for camptothecin: drug release and cytotoxicity against cancer cells. Ultrasonics. 2009;49(1): 39-46.
83. Shenderova A, Burke TG, Schwendeman SP. Stabilization of 10-hydroxycamptothecin in poly(lactide-co-glycolide) microsphere delivery vehicles. Pharm Res. 1997;14(10):1406-1414.
84. Zhang L, Yang M, Wang Q, et al. 10-Hydroxycamptothecin loaded nanoparticles: preparation and antitumor activity in mice. J Control Release. 2007;119(2):153-162.
85. Hatefi A, Amsden B. Camptothecin delivery methods. Pharm Res. 2002;19(10):1389-1399.
86. Ziomkowska B, Kruszewski S, Siuda R, et al. Deactivation of camptothecin determined by factor analysis of steady-state fluorescence and absorption spectra. Optica Applicata. 2006;36(1):137-146.
87. Cortesi R, Esposito E, Maietti A, Menegatti E, Nastruzzi C. Formulation study for the antitumour drug camptothecin: liposomes, micellar solutions and a microemulsion. Int J Pharm. 1997;159(1):95-103.
88. Miura H, Onishi H, Sasatsu M, Machida Y. Antitumor characteristics of methoxypolyethylene glycol-poly(DL-lactic acid) nanoparticles containing camptothecin. J Control Release. 2004;97(1):101-113.
89. Vergara D, Bellomo C, Zhang X, et al. Lapatinib/Paclitaxel polyelectrolyte nanocapsules for overcoming multidrug resistance in ovarian cancer. Nanomedicine. 2012;8(6):891-899.
90. Fonseca C, Simões S, Gaspar R. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release. 2002;83(2):273-286.
91. Sonnemann J, Palani CD, Wittig S, et al. Anticancer effects of the p53 activator nutlin-3 in Ewing's sarcoma cells. Eur J Cancer. 2011;47(9): 1432-1441.
92. Song XR, Cai Z, Zheng Y, et al. Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles. Eur J Pharm Sci. 2009;37(3-4):300-305.
93. Cesur H, Rubinstein I, Pai A, Onyüksel H. Self-associated indisulam in phospholipid-based nanomicelles: a potential nanomedicine for cancer. Nanomedicine. 2009;5(2):178-183.
94. Mohanty C, Sahoo SK. The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation. Biomaterials. 2010;31(25):6597-6611.
95. Das RK, Kasoju N, Bora U. Encapsulation of curcumin in alginatechitosan-pluronic composite nanoparticles for delivery to cancer cells. Nanomedicine. 2010;6(1):153-160.
96. Anitha A, Maya S, Deepa N, et al. Eff icient water soluble O-carboxymethyl chitosan nanocarrier for the delivery of curcumin to can cells. Carbohydr Polym. 2011;83(2):452-461.
97. Tiyaboonchai W, Tungpradit W, Plianbangchang P. Formulation and characterization of curcuminoids loaded solid lipid nanoparticles. Int J Pharm. 2007;337(1-2):299-306.
98. Anand P, Nair HB, Sung B, et al. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol. 2010;79(3):330-338.
99. Dhule SS, Penfornis P, Frazier T, et al. Curcumin-loaded γ-cyclodextrin liposomal nanoparticles as delivery vehicles for osteosarcoma. Nanomedicine. 2012;8(4):440-451.
100. Kundu P, Mohanty C, Sahoo SK. Antiglioma activity of curcuminloaded lipid nanoparticles and its enhanced bioavailability in brain tissue for effective glioblastoma therapy. Acta Biomater. 2012;8(7): 2670-2687.
101. Liu J, Xu L, Liu C, et al. Preparation and characterization of cationic curcumin nanoparticles for improvement of cellular uptake. Carbohydr Polym. 2012;90(1):16-22.
102. Barenholz Y. Liposome application: problems and prospects. Curr Opin Colloid Interface Sci. 2001;6(1):66-77.
103. Nishiyama N, Kataoka K. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol Ther. 2006;112(3):630-648.
104. Bellott R, Pouna P, Robert J. Separation and determination of liposomal and non-liposomal daunorubicin from the plasma of patients treated with Daunoxome. J Chromatogr B Biomed Sci Appl. 2001;757(2): 257-267.
105. Junghanns JU, Müller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine. 2008;3(3):295-309.
106. Nijhara R, Balakrishnan K. Bringing nanomedicines to market: regulatory challenges, opportunities, and uncertainties. Nanomedicine. 2006;2(2):127-136.
107. Hawkins MJ, Soon-Shiong P, Desai N. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev. 2008;60(8): 876-885.
108. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release. 2008;132(3):171-183.
109. Nakanishi T, Fukushima S, Okamoto K, et al. Development of the polymer micelle carrier system for doxorubicin. J Control Release. 2001;74(1-3):295-302.
110. Tsukioka Y, Matsumura Y, Hamaguchi T, Koike H, Moriyasu F, Kakizoe T. Pharmaceutical and biomedical differences between micellar doxorubicin (NK911) and liposomal doxorubicin (Doxil). Jpn J Cancer Res. 2002;93(10):1145-1153.
111. Shea JE, Nam KH, Rapoport N, Scaife CL. Genexol inhibits primary tumour growth and metastases in gemcitabine-resistant pancreatic ductal adenocarcinoma. HPB (Oxford). 2011;13(3):153-157.
112. Alakhov V, Klinski E, Li SM, et al. Block copolymer-based formulation of doxorubicin. From cell screen to clinical trials. Colloids Surf B Biointerfaces. 1999;16(1-4):113-134.
113. Danson S, Ferry D, Alakhov V, et al. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br J Cancer. 2004;90(11):2085-2091.
114. Bogunia-Kubik K, Sugisaka M. From molecular biology to nanotechnology and nanomedicine. Biosystems. 2002;65(2-3):123-138.
115. Fattal E, Bochot A. State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers. Int J Pharm. 2008;364(2):237-248.
116. Nafee N, Taetz S, Schneider M, Schaefer UF, Lehr CM. Chitosancoated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides. Nanomedicine. 2007;3(3):173-183.
117. Zhong J, Yao X, Li DL, et al. Large scale preparation of midkine antisense oligonucleotides nanoliposomes by a cross-flow injection technique combined with ultrafiltration and high-pressure extrusion procedures. Int J Pharm. 2013;441(1-2):712-720.
118. Sioss JA, Bhiladvala RB, Pan W, et al. Nanoresonator chip-based RNA sensor strategy for detection of circulating tumor cells: response using PCA3 as a prostate cancer marker. Nanomedicine. 2012;8(6):1017-1025.
119. Veiseh O, Gunn JW, Zhang M. Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv Drug Deliv Rev. 2010;62(3):284-304.
120. Mura S, Couvreur P. Nanotheranostics for personalized medicine. Adv Drug Deliv Rev. 2012;64(13):1394-1416.
121. Shiraishi K, Endoh R, Furuhata H, et al. A facile preparation method of a PFC-containing nano-sized emulsion for theranostics of solid tumors. Int J Pharm. 2011;421(2):379-387.
122. Shalviri A, Foltz WD, Cai P, Rauth AM, Wu XY. Multifunctional terpolymeric MRI contrast agent with superior signal enhancement in blood and tumor. J Control Release. 2013;167(1):11-20.
123. He Q, Ma M, Wei C, Shi J. Mesoporous carbon@silicon-silica nanotheranostics for synchronous delivery of insoluble drugs and luminescence imaging. Biomaterials. 2012;33(17):4392-4402.
124. Howell M, Mallela J, Wang C, et al. Manganese-loaded lipid-micellar theranostics for simultaneous drug and gene delivery to lungs. J Control Release. 2013;167(2):210-218.
125. Mahmoudi M, Sant S, Wang B, Laurent S, Sen T. Superparamagnetic iron oxide nanoparticles (SPIONs): development, surface modification and applications in chemotherapy. Adv Drug Deliv Rev. 2011;63(1-2):24-46.
126. Tsay JM, Trzoss M, Shi L, et al. Singlet oxygen production by Peptidecoated quantum dot-photosensitizer conjugates. J Am Chem Soc. 2007;129(21):6865-6871.
127. Spyratou E, Makropoulou M, Mourelatou EA, Demetzos C. Biophotonic techniques for manipulation and characterization of drug delivery nanosystems in cancer therapy. Cancer Lett. 2012;327(1-2): 111-122.
128. Allison RR, Mota HC, Bagnato VS, Sibata CH. Bio-nanotechnology and photodynamic therapy state of the art review. Photodiagnosis Photodyn Ther. 2008;5(1):19-28.
129. García-Díaz M, Kawakubo M, Mroz P, et al. Cellular and vascular effects of the photodynamic agent temocene are modulated by the delivery vehicle. J Control Release. 2012;162(2):355-363.
130. Ling D, Bae BC, Park W, Na K. Photodynamic efficacy of photosensitizers under an attenuated light dose via lipid nano-carrier-mediated nuclear targeting. Biomaterials. 2012;33(21):5478-5486.
131. Sobolev AS, Jans DA, Rosenkranz AA. Targeted intracellular delivery of photosensitizers. Prog Biophys Mol Biol. 2000;73(1):51-90.
132. Roy I, Ohulchanskyy TY, Pudavar HE, et al. Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: a novel drug-carrier system for photodynamic therapy. J Am Chem Soc. 2003;125(26):7860-7865.
133. Kiesslich T, Berlanda J, Plaetzer K, Krammer B, Berr F. Comparative characterization of the efficiency and cellular pharmacokinetics of Foscan- and Foslip-based photodynamic treatment in human biliary tract cancer cell lines. Photochem Photobiol Sci. 2007;6(6):619-627.
134. Sibata MN, Tedesco AC, Marchetti JM. Photophysicals and photochemicals studies of zinc(II) phthalocyanine in long time circulation micelles for photodynamic therapy use. Eur J Pharm Sci. 2004;23(2):131-138.
135. Khdair A, Handa H, Mao G, Panyam J. Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance in vitro. Eur J Pharm Biopharm. 2009;71(2):214-222.
136. Ohulchanskyy TY, Roy I, Goswami LN, et al. Organically modified silica nanoparticles with covalently incorporated photosensitizer for photodynamic therapy of cancer. Nano Lett. 2007;7(9): 2835-2842.